search
Back to results

Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics

Primary Purpose

Foot, Diabetic

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Personalized Nutritional Intervention
Sponsored by
Maimónides Biomedical Research Institute of Córdoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Foot, Diabetic focused on measuring Dietary Supplementations, Wound Healing, Diabetes Mellitus, Malnutrition

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signature of the informed consent
  • Age between 50 and 80 years
  • Diagnosis of Diabetes Mellitus for more than 1 year
  • Documented diagnosis of peripheral artery disease
  • HbA1c < 9%
  • Category 5 in the Rutherford-Becker classification

Exclusion Criteria:

  • Poor cognitive function, dementia or psychiatric conditions
  • Osteomyelitis, gangrene, malignancy or immunocompromised disease
  • Thromboangiitis obliterans or Buerger's disease
  • Clinical evidence of invasive infection in the target limb requiring IV antibiotherapy
  • Presence of neuropathic ulcers only
  • Human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) positive.

Sites / Locations

  • Hospital Universitario Reina Sofía de CórdobaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Nutritional Intervention (NI)

Control (C)

Arm Description

In addition to the usual treatment, will receive dietary advice and a nutritional supplement, according to the results of their evaluation in the Endocrinology Service

Who will continue with their usual treatments in the Diabetic Foot Unit and they will receive dietary advice

Outcomes

Primary Outcome Measures

Ulcer evaluation
Change from baseline in size ulcer assessed by picture, including ruler to measure their size

Secondary Outcome Measures

Composite measure of markers of nutritional status
Change from baseline in nutritional status assessed from blood samples
Composite measure of haemogram
Change from baseline in haemogram assessed from blood samples
Hemoglobin A1c (HbA1c) Test for Diabetes
Change from baseline in HbA1c (%) assessed from blood samples
Measure of markers of nutritional status, include to thyrotropin
Change from baseline in thyrotropin (mlU/L) assessed from blood samples
Ultrasensitive C-reactive Protein (CRP) test
Change from baseline in CRP (mg/L) assessed from blood samples
Quantification of circulating endothelial progenitor cells (EPC)
Change from baseline in total CD34+ or CD133+ cells expressing vascular endothelial growth factor receptor 2 (VEGFR2) analyzed by flow cytometry
Concentration of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor A (VEGFA)
Change from baseline in concentration of SDF-1 and VEGFA factors in serum by ELISA

Full Information

First Posted
January 20, 2022
Last Updated
October 23, 2023
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Collaborators
Instituto de Salud Carlos III, Hospital Universitario Reina Sofia de Cordoba
search

1. Study Identification

Unique Protocol Identification Number
NCT05243368
Brief Title
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Official Title
Evaluation of Personalized Nutritional Intervention Together With the Application of MSC-derived Exosomes on the Regenerative Capacity and Wound Healing of Cutaneous Ulcers in Diabetics
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 20, 2023 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maimónides Biomedical Research Institute of Córdoba
Collaborators
Instituto de Salud Carlos III, Hospital Universitario Reina Sofia de Cordoba

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The ageing population and the increase in diabetes raise the prevalence of chronic skin ulcers (CCU). In diabetics, precursor cell mobilization decreases. In wounds, the inflammation is prolonged and oxidative stress increases. This is an unfavorable microenvironment for healing. A major risk factor in the development of CCU is nutritional deficiency. Healing needs energy and nutrients for regeneration. In diabetics the malnutrition can be more than 60%. However, although the provision of certain nutrients can improve the healing capacity, it is not a common clinical practice to nutritionally evaluate diabetic with CCU. Exosomes are extracellular vesicles that reflect the physiological state of the cells producing them. Stem cell derivatives exosomes are rich in factors, that can provide a favorable microenvironment for tissue regeneration. The aim of this project is to develop a therapeutic process to accelerate the healing of diabetic CCU, based on the correction of nutritional deficiencies, to improve the regenerative capacity, together with the application of exosomes from mesenchymal stem-cell (MSC) in the wound, creating a microenvironment that favors tissue regeneration. For this, a pilot clinical trial with diabetic patients with CCU is proposed, to evaluate the effect of personalized nutritional supplementation on healing and regenerative capacity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Foot, Diabetic
Keywords
Dietary Supplementations, Wound Healing, Diabetes Mellitus, Malnutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nutritional Intervention (NI)
Arm Type
Experimental
Arm Description
In addition to the usual treatment, will receive dietary advice and a nutritional supplement, according to the results of their evaluation in the Endocrinology Service
Arm Title
Control (C)
Arm Type
No Intervention
Arm Description
Who will continue with their usual treatments in the Diabetic Foot Unit and they will receive dietary advice
Intervention Type
Dietary Supplement
Intervention Name(s)
Personalized Nutritional Intervention
Intervention Description
Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
Primary Outcome Measure Information:
Title
Ulcer evaluation
Description
Change from baseline in size ulcer assessed by picture, including ruler to measure their size
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Secondary Outcome Measure Information:
Title
Composite measure of markers of nutritional status
Description
Change from baseline in nutritional status assessed from blood samples
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Composite measure of haemogram
Description
Change from baseline in haemogram assessed from blood samples
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Hemoglobin A1c (HbA1c) Test for Diabetes
Description
Change from baseline in HbA1c (%) assessed from blood samples
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Measure of markers of nutritional status, include to thyrotropin
Description
Change from baseline in thyrotropin (mlU/L) assessed from blood samples
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Ultrasensitive C-reactive Protein (CRP) test
Description
Change from baseline in CRP (mg/L) assessed from blood samples
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Quantification of circulating endothelial progenitor cells (EPC)
Description
Change from baseline in total CD34+ or CD133+ cells expressing vascular endothelial growth factor receptor 2 (VEGFR2) analyzed by flow cytometry
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Concentration of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor A (VEGFA)
Description
Change from baseline in concentration of SDF-1 and VEGFA factors in serum by ELISA
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Other Pre-specified Outcome Measures:
Title
Nutritional Risk
Description
Change from baseline in nutritional risk assessed by Malnutrition Universal Screening Tool (MUST)
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Diagnosis of malnutrition
Description
Change from baseline in diagnosis of malnutrition assessed by Global Leadership Initiative on malnutrition (GLIM criteria)
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Sarcopenia
Description
Change from baseline in sarcopenia assessed by SARC-F
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Handgrip Strength
Description
Change from baseline in handgrip strength assessed by dynamometry
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Body weight and height
Description
Body weight and height will be combined to report body mass index (BMI) in kg/m^2. Change from baseline in BMI
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Tricipital skinfold
Description
Change from baseline in tricipital skinfold using a skinfold caliper
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Arm circumference
Description
Change from baseline in arm circumference in centimeters (cm)
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Waist and hip circumferences
Description
waist and hip circumferences (cm) will be combined to report Waist and Hip Ratio (WHR). Change from baseline in WHR
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Body Fat
Description
Change from baseline in body fat assessed by multifrequency bioimpedaciometry and bioelectrical impedance vector analysis
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Muscle Mass
Description
Change from baseline in muscle mass assessed by multifrequency bioimpedaciometry and bioelectrical impedance vector analysis
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Title
Hydration status
Description
Change from baseline in hydration status assessed by multifrequency bioimpedaciometry and bioelectrical impedance vector analysis
Time Frame
Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signature of the informed consent Age between 50 and 80 years Diagnosis of Diabetes Mellitus for more than 1 year Documented diagnosis of peripheral artery disease HbA1c < 9% Category 5 in the Rutherford-Becker classification Exclusion Criteria: Poor cognitive function, dementia or psychiatric conditions Osteomyelitis, gangrene, malignancy or immunocompromised disease Thromboangiitis obliterans or Buerger's disease Clinical evidence of invasive infection in the target limb requiring IV antibiotherapy Presence of neuropathic ulcers only Human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) positive.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antonio Casado-Díaz, PhD
Phone
957213814
Email
bb1cadia@uco.es
First Name & Middle Initial & Last Name or Official Title & Degree
Marta Camacho-Cardenosa, PhD
Email
marta.camacho@imibic.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonio Casado-Díaz, PhD
Organizational Affiliation
Maimonides Biomedical Research Institute of Cordoba
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alfonso Calañas, PhD
Organizational Affiliation
Hospital Universitario Reina Sofía
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario Reina Sofía de Córdoba
City
Córdoba
State/Province
Andalucía
ZIP/Postal Code
14004
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alfonso Calañas, PhD
Phone
957010000
Email
alfonso.calanas.sspa@juntadeandalucia.es

12. IPD Sharing Statement

Citations:
PubMed Identifier
24867069
Citation
Armstrong DG, Hanft JR, Driver VR, Smith AP, Lazaro-Martinez JL, Reyzelman AM, Furst GJ, Vayser DJ, Cervantes HL, Snyder RJ, Moore MF, May PE, Nelson JL, Baggs GE, Voss AC; Diabetic Foot Nutrition Study Group. Effect of oral nutritional supplementation on wound healing in diabetic foot ulcers: a prospective randomized controlled trial. Diabet Med. 2014 Sep;31(9):1069-77. doi: 10.1111/dme.12509. Epub 2014 Jun 19.
Results Reference
background
PubMed Identifier
32756299
Citation
Basiri R, Spicer MT, Levenson CW, Ormsbee MJ, Ledermann T, Arjmandi BH. Nutritional Supplementation Concurrent with Nutrition Education Accelerates the Wound Healing Process in Patients with Diabetic Foot Ulcers. Biomedicines. 2020 Aug 3;8(8):263. doi: 10.3390/biomedicines8080263.
Results Reference
background
PubMed Identifier
30181091
Citation
Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C; GLIM Core Leadership Committee; GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002. Epub 2018 Sep 3.
Results Reference
background
PubMed Identifier
29145757
Citation
Haughey L, Barbul A. Nutrition and Lower Extremity Ulcers: Causality and/or Treatment. Int J Low Extrem Wounds. 2017 Dec;16(4):238-243. doi: 10.1177/1534734617737639. Epub 2017 Nov 16.
Results Reference
background
PubMed Identifier
33045979
Citation
Kurian SJ, Miraj SS, Benson R, Munisamy M, Saravu K, Rodrigues GS, Rao M. Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective. Curr Diabetes Rev. 2021;17(4):512-521. doi: 10.2174/1573399816999201012195735.
Results Reference
background
PubMed Identifier
23810110
Citation
Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013 Aug;14(8):531-2. doi: 10.1016/j.jamda.2013.05.018. Epub 2013 Jun 25. No abstract available.
Results Reference
background
PubMed Identifier
23251271
Citation
Zhang SS, Tang ZY, Fang P, Qian HJ, Xu L, Ning G. Nutritional status deteriorates as the severity of diabetic foot ulcers increases and independently associates with prognosis. Exp Ther Med. 2013 Jan;5(1):215-222. doi: 10.3892/etm.2012.780. Epub 2012 Oct 30.
Results Reference
background

Learn more about this trial

Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics

We'll reach out to this number within 24 hrs